Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Abeona Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 4.3 across the same-window beat baseline.
Last mentioned: Mar 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Abeona Therapeutics is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 4.3 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.9. ZEVASKYN® appears in 1 tracked Healthcare story from March 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ZEVASKYN®. Shared-story counts are live from our verified record — not editorial picks.
Abeona Therapeutics is set to report its fiscal year 2025 results, marking its transition from a clinical-stage developer to a commercial-stage biopharmaceutical entity. The primary focus for investors is the commercial trajectory of ZEVASKYN® for recessive dystrophic epidermolysis bullosa (RDEB) and the company's ability to manage complex cell therapy logistics.
Source: Seeking Alpha · Seeking Alpha
ZEVASKYN® is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
